EN DE
Watch PHARMESIS INTERNATIONAL LTD. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

PHARMESIS INTERNATIONAL LTD. (BFK) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of PHARMESIS INTERNATIONAL LTD. stock S$0.21, price S$0.08, upside +152.4%, quality 38 out of 100. Rating: strongly undervalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG

PI PHARMESIS INTERNATIONAL LTD. logo Thin data Nov 14, 2026

PHARMESIS INTERNATIONAL LTD.

BFK · SG

Cheap (60% below fair value), but weak company and price moving sideways: meets 1 of 3 rules.

Get notified free when this changes
Fair value 0.2070 SGD · Strongly undervalued 
Generates free cash flow 
Even on cautious assumptions the value is 98% above the price (0.1620 SGD). 
Price moving sideways (no uptrend) 
Quality 38/100 
Weak Growth (revenue 5y −1.5 %/yr in SGD) 
Loss-making · -25.7% net margin (TTM) 
Trails peers (4/11) 
Narrow moat 6/100 · thin data
Thin data 
⚠ Thinly traded⚠ Small free float
Watch PHARMESIS INTERNATIONAL LTD. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.6360 SGD 0.0753 SGD Fair Value 0.2070 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range 0.0753 SGD – 0.6360 SGD · fair‑value band 0.1620 SGD – 0.2790 SGD · the 0.0820 SGD price screens below the 0.2070 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow PHARMESIS INTERNATIONAL in your weekly email

Every Wednesday you see whether PHARMESIS INTERNATIONAL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China.

Show moreShow less

The company operates through three segments: Western drugs/TCH Procurement, TCM formulated drugs/IP Rental, and Distribution. It provides prescribed products and over-the-counter drugs.

The company offers Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for rheumatoid arthritis and other rheumatic diseases treatment.

It also provides Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice and clear heat toxin; Shulinghou for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Fu Yang for the treatment skin pruritus and urticaria; and Xiong Dan Chuan Bei for the treatment of phlegm and cough.

Further, the company distributes chemical drugs, biological raw products, TCM products, antibiotics, and antibiotic agents. The company provides western medicine products under the Kinna brand name; and TCM formulated products under the Longlife brand name.

Pharmesis International Ltd. was founded in 1996 and is based in Singapore.

Stock analysis

PHARMESIS INTERNATIONAL LTD. (BFK) currently trades at 0.0820 SGD, while our model-based Fair Value estimate is 0.2070 SGD, implying the stock looks roughly 60% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 0.2350 SGD per share, and 7 of the 7 models we run sit above the 0.0820 SGD price.

Bear case: the Multiples group reads lowest at 0.1200 SGD, and 0 of the 7 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.1620 SGD (bear) to 0.2790 SGD (bull), the price of 0.0820 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

PHARMESIS INTERNATIONAL LTD. reported revenue of 43.8M CNY in FY2025 versus 52.8M CNY in FY2021, a compound −4.6%/yr. Reported net income was −4.3M CNY in FY2025.

Key figures

Market cap 2.6M SGD (≈ $2.0M) Micro · P/S ratio 0.11 · EPS (TTM) −0.0400 SGD · Net margin −9.8% · Return on equity −13.1% · Return on assets (EBIT) −1.6% (5-year average) · Operating margin −34.3% · Revenue (TTM) 28.4M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 80% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 152%, BFK screens cheaper than that median.

Fair Value models

Bear 0.1620 SGD Fair Value 0.2070 SGD Bull 0.2790 SGD
Price 0.0820 SGD · Upside +152.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 0.1900 SGD 0.2500 SGD 0.3600 SGD 79
Growth DCF 0.2000 SGD 0.2500 SGD 0.3500 SGD 77
5Y Revenue Exit 0.1600 SGD 0.2200 SGD 0.3000 SGD 71
All 7 models by family
DCF Models
FCF DCF 0.1900 SGD 0.2500 SGD 0.3600 SGD 79
5Y Revenue Exit 0.1600 SGD 0.2200 SGD 0.3000 SGD 71
10Y Revenue Exit 0.1700 SGD 0.2100 SGD 0.2600 SGD 66
Multiples
EV/Revenue 0.0700 SGD 0.1200 SGD 0.1800 SGD 49
Asset-Based
NCAV (Graham) 0.1600 SGD 0.2200 SGD 0.3300 SGD 51
Growth DCF
Growth DCF 0.2000 SGD 0.2500 SGD 0.3500 SGD 77
Rev-Margin DCF 0.1600 SGD 0.2200 SGD 0.3000 SGD 71

Open the full fair value analysis →

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 11
Are margins and returns getting better?
Cashflow 52
Do the profits arrive as real cash?
Financial strength 47
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 19/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−35.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
Start year 2020 (pandemic). Over 10 years: −3.5% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.5% (2020) → −12.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−13.8%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −15.3% a year for the price.

Watch BFK, get fair value alerts →

Compare PHARMESIS INTERNATIONAL LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside +152.4% · Top 25%
Profitability
Return on assets −4.5% · Bottom 25%
Net margin (12 months) −25.7% · Bottom 25%
Operating margin (12 months) −34.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −56.4% · Bottom 25%
Dividend yield (12 months) 0.0% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.24× · Cheapest 25%
P/S (12 months) 0.47× · Cheapest 25%
Price / free cash flow (fiscal year) 5.7× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 19
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs BFK
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs BFK
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs BFK
Haleon plc HLN $9.20 $8.47 −8% vs BFK
Merck KGaA MRK €149.70 €108.83 −27% vs BFK
Galderma Group GALD CHF 191.00 CHF 112.46 −41% vs BFK
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs BFK
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs BFK
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs BFK
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs BFK

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PHARMESIS INTERNATIONAL LTD.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "PHARMESIS INTERNATIONAL LTD. Fair Value". https://www.fairvalue-calculator.com/stock/BFK

Frequently asked questions

Is PHARMESIS INTERNATIONAL LTD. (BFK) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of 0.2070 SGD versus a price of 0.0820 SGD, about +152% upside (undervalued).
What is the fair value of BFK?
Our model-based fair value for PHARMESIS INTERNATIONAL LTD. is 0.2070 SGD (as of Nov 14, 2026), built from audited fundamentals. The current price: 0.0820 SGD.
What is the quality score of BFK?
PHARMESIS INTERNATIONAL LTD. has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PHARMESIS INTERNATIONAL LTD. (BFK)?
Our model-based price target is the fair value of 0.2070 SGD (as of Nov 14, 2026) from 7 valuation models. Cautious scenario 0.1620 SGD, optimistic scenario 0.2790 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the PHARMESIS INTERNATIONAL LTD. stock forecast for 2026?
Our models put fair value at 0.2070 SGD, about +152% upside versus a price of 0.0820 SGD (undervalued). Cautious scenario 0.1620 SGD, optimistic scenario 0.2790 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of PHARMESIS INTERNATIONAL LTD. (BFK)?
PHARMESIS INTERNATIONAL LTD. reported trailing-twelve-month revenue of about 28.4M CNY (latest available figure, as of Nov 14, 2026).
What growth is priced into PHARMESIS INTERNATIONAL LTD. (BFK)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at PHARMESIS INTERNATIONAL LTD. shrinks by 13.8 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 1.5 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of BFK use?
Our models discount PHARMESIS INTERNATIONAL LTD. at 9.5 %: a base by market capitalisation (nano), country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PHARMESIS INTERNATIONAL LTD. that is -13.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has PHARMESIS INTERNATIONAL LTD. (BFK) delivered so far?
Over the past 5 years revenue at PHARMESIS INTERNATIONAL LTD. shrank 1.5 % a year. The price currently implies free-cash-flow growth of -13.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PHARMESIS INTERNATIONAL LTD. (BFK) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into PHARMESIS INTERNATIONAL LTD. (-13.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PHARMESIS INTERNATIONAL LTD. (BFK)?
The free-cash-flow yield on the price is 17.57 %: that much free cash flow PHARMESIS INTERNATIONAL LTD. produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PHARMESIS INTERNATIONAL LTD. (BFK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PHARMESIS INTERNATIONAL LTD. it is 0.2070 SGD per share (as of Nov 14, 2026), against a price of 0.0820 SGD. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is PHARMESIS INTERNATIONAL LTD. stock overvalued or undervalued in 2026?
As of Nov 14, 2026, BFK trades below its calculated fair value: price 0.0820 SGD, fair value 0.2070 SGD, a gap of about +152% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BFK?
No. The price is what the market pays today (0.0820 SGD); the fair value is what the company's own numbers justify (0.2070 SGD). For PHARMESIS INTERNATIONAL LTD. the two are 0.1250 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is PHARMESIS INTERNATIONAL LTD. worth?
The market values PHARMESIS INTERNATIONAL LTD. at about 2.6M SGD (market capitalisation, as of Nov 14, 2026). Per share that is 0.0820 SGD; our models calculate a fair value of 0.2070 SGD per share.
What do the bullish and bearish scenarios say about BFK?
Our models span a range for PHARMESIS INTERNATIONAL LTD.: cautious scenario 0.1620 SGD, base 0.2070 SGD, optimistic 0.2790 SGD per share (as of Nov 14, 2026, price 0.0820 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PHARMESIS INTERNATIONAL LTD. (BFK)?
Balance-sheet figures for PHARMESIS INTERNATIONAL LTD. (as of Nov 14, 2026): return on equity −13.1%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is BFK from its 52-week high?
PHARMESIS INTERNATIONAL LTD. trades at 0.0820 SGD, about 80% below its 52-week high of 0.4150 SGD and 6% above the low of 0.0770 SGD (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2070 SGD is for.
Which stocks are comparable to PHARMESIS INTERNATIONAL LTD.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PHARMESIS INTERNATIONAL LTD. stock attractive at the current price?
The data as of Nov 14, 2026: price 0.0820 SGD, calculated fair value 0.2070 SGD (+152%), Quality Score 38/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BFK calculated?
We run PHARMESIS INTERNATIONAL LTD. through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 0.2070 SGD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. PHARMESIS INTERNATIONAL LTD. currently trades 60% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PHARMESIS INTERNATIONAL LTD. (BFK)?
The closing price on Nov 16, 2026 was 0.0820 SGD. Our model-based fair value is 0.2070 SGD, about +152% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PHARMESIS INTERNATIONAL LTD. right now?
The large discount to fair value meets weak quality (38/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (0.1620 SGD). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of PHARMESIS INTERNATIONAL LTD.

How large is the market capitalisation of PHARMESIS INTERNATIONAL LTD. (BFK)?
The market capitalisation of PHARMESIS INTERNATIONAL LTD. is 2.6M SGD (≈ $2.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PHARMESIS INTERNATIONAL LTD. (BFK)?
The price-to-sales ratio of PHARMESIS INTERNATIONAL LTD. is 0.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PHARMESIS INTERNATIONAL LTD. (BFK)?
Earnings per share at PHARMESIS INTERNATIONAL LTD. are −0.0400 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of PHARMESIS INTERNATIONAL LTD. (BFK)?
The net margin of PHARMESIS INTERNATIONAL LTD. is −9.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PHARMESIS INTERNATIONAL LTD. (BFK)?
The return on equity (ROE) of PHARMESIS INTERNATIONAL LTD. is −13.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PHARMESIS INTERNATIONAL LTD. (BFK)?
On an EBIT basis the return on assets of PHARMESIS INTERNATIONAL LTD. is −1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PHARMESIS INTERNATIONAL LTD. (BFK)?
The operating margin of PHARMESIS INTERNATIONAL LTD. is −34.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PHARMESIS INTERNATIONAL LTD. (BFK)?
Revenue at PHARMESIS INTERNATIONAL LTD. is down 56.4% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does PHARMESIS INTERNATIONAL LTD. (BFK) carry?
The net debt of PHARMESIS INTERNATIONAL LTD. is 10.7M CNY (fiscal year 2025, ≈ 4.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch PHARMESIS INTERNATIONAL LTD. in the live analysis

One click puts PHARMESIS INTERNATIONAL LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.